These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37156065)

  • 1. Current and emerging therapies for Achondroplasia: The dawn of precision medicine.
    Dardenne E; Ishiyama N; Lin TA; Lucas MC
    Bioorg Med Chem; 2023 May; 87():117275. PubMed ID: 37156065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.
    Wrobel W; Pach E; Ben-Skowronek I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR3 targeting strategies for achondroplasia.
    Laederich MB; Horton WA
    Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding horizons of achondroplasia treatment: current options and future developments.
    Fafilek B; Bosakova M; Krejci P
    Osteoarthritis Cartilage; 2022 Apr; 30(4):535-544. PubMed ID: 34864168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vosoritide: First Approval.
    Duggan S
    Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
    Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
    Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTH has the potential to rescue disturbed bone growth in achondroplasia.
    Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
    Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New treatments for achondroplasia may be efficacious in other forms of short stature].
    Nilsson O
    Lakartidningen; 2021 Feb; 118():. PubMed ID: 33647161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
    Legeai-Mallet L
    Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies for Achondroplasia: changing the rules of the game.
    Kumble S; Savarirayan R
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):425-431. PubMed ID: 34758681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vosoritide in the treatment of achondroplasia.
    Paton DM
    Drugs Today (Barc); 2022 Sep; 58(9):451-456. PubMed ID: 36102905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A registry of achondroplasia: a 6-year experience from the Czechia and Slovak Republic.
    Pesl M; Verescakova H; Skutkova L; Strenkova J; Krejci P
    Orphanet J Rare Dis; 2022 Jun; 17(1):229. PubMed ID: 35710503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fibroblast growth factor receptor and achondroplasia].
    Tanaka H
    Clin Calcium; 2006 Nov; 16(11):1888-93. PubMed ID: 17079857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
    van Ravenswaaij-Arts CM; Losekoot M
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achondroplasia and enchondromatosis: report of three boys.
    Numakura C; Kobayashi H; Hasegawa Y; Adachi M; Kim OH; Nishimura G
    Skeletal Radiol; 2007 Jun; 36 Suppl 1():S29-33. PubMed ID: 16763840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
    Tsai FJ; Tsai CH; Chang JG; Wu JY
    Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
    [No Abstract]   [Full Text] [Related]  

  • 17. Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study.
    Savarirayan R; Baratela W; Butt T; Cormier-Daire V; Irving M; Miller BS; Mohnike K; Ozono K; Rosenfeld R; Selicorni A; Thompson D; White KK; Wright M; Fredwall SO
    Orphanet J Rare Dis; 2022 Jun; 17(1):224. PubMed ID: 35698202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mutations of FGFR3 gene cause 3 types of nanisms with variably severity: achondroplasia, thanatophoric nanism and hypochondroplasia].
    Rousseau F; Bonaventure J; Le Merrer M; Maroteaux P; Munnich A
    Ann Endocrinol (Paris); 1996; 57(3):153. PubMed ID: 8949408
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
    Tanaka H
    Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
    Manickam K; Donoghue DJ; Meyer AN; Snyder PJ; Prior TW
    Am J Med Genet A; 2014 Jan; 164A(1):243-50. PubMed ID: 24352917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.